Inogen, Inc · NASDAQ:INGN
Inogen — Investor Presentation (January 2021)
21 slides from Inogen's investor presentation, Jan 11, 2021
Slide 1: Company Overview January 2021
Company Overview January 2021 Exhibit 99.1
Slide 2: Notice Regarding Forward-Looking Statements
Notice Regarding Forward-Looking Statements These slides and the accompanying oral presentation (the “Presentation”) include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based
Slide 3: Inogen POC Offers Freedom and Mobility
Inogen POC Offers Freedom and Mobility Stationary oxygen concentrator + Regular oxygen tank delivery Delivery Model Inogen Model 4.7 pounds (single battery) Pulse-dose, Intelligent Delivery Technology Run time up to 13 hours with a double battery A/C adaptable Conforms to all applicable FAA requirem
Slide 4: Traditional O2 Therapy Challenged by Market Dynamics
Traditional O2 Therapy Challenged by Market Dynamics Traditional O2 P Inogen Cost effective Maximizes mobility P P O O O Relevance today >50% reduction to Medicare reimbursement rates Oxygen delivery has high infrastructure and variable costs Ambulatory O2 2x survival; 60% fewer hospital days1 Uti
Slide 5: Product Performance Drives Leadership Position
Product Performance Drives Leadership Position Effectiveness Design Convenience
Slide 6: Building the Inogen Brand
Building the Inogen Brand Targeted advertising Consumer preference Domestic direct-to-consumer sales ($M) Domestic business-to-business sales ($M) +37.4% 4-year CAGR Founded in patient preference +32.6% 4-year CAGR
Slide 7: U.S. Market Dynamics Favor POC Adoption by HME Providers
Low monthly reimbursement is expected to continue to challenge the oxygen delivery model and favor POC adoption HME restructuring challenges, capital constraints, and limited cash flow are expected to lead to “lumpy” order activity We believe COVID-19 has reduced new COPD patient referrals due to re
Slide 8: Innovation to Stay at Forefront of Customer Preference
Innovation to Stay at Forefront of Customer Preference
Slide 9: Globally Diversified Revenue
Globally Diversified Revenue 2019 Revenue: $361.9M YTD September 30, 2020 Revenue: $234.5M Sales in 47 Countries Worldwide revenue
Slide 10: Historical Revenue & Strong Balance Sheet
Historical Revenue & Strong Balance Sheet Revenue ($M) 10 Year CAGR of 42.2% As of September 30, 2020
Slide 11: Driving Future Revenue Growth
Driving Future Revenue Growth 300 inside sales reps* Focusing on sales rep productivity including close rates Increased utilization of leads to drive rentals 14 U.S. and 9 Int’l B2B sales & support team* Strong private label partnership Distribution in 46 international countries Developing reg. & sa
Slide 12: Company Highlights
Company Highlights Market leader in large, global, underpenetrated market DTC model enables innovation and customer access Differentiated product portfolio with commitment to R&D Experienced management team recognized as leaders in the respiratory homecare market Attractive financial profile
Slide 13: Supplemental Information
inegen nental Information oxygen. anytime. anywhere.
Slide 14: High Standards of Compliance and Regulations
510(k) clearance by the FDA FDA registered manufacturing facilities Conforms to all applicable FAA requirements for use on commercial aircraft Quality Management System certified to comply with ISO 13485 for the design, development, manufacture, distribution and service of oxygen concentrators, non-
Slide 15: Estimated U.S. Medicare Penetration of POCs
Estimated U.S. Medicare Penetration of POCs We believe POCs remain under penetrated Based on 2019 U.S. Medicare claims data, ambulatory patients account for 77.8% of total LTOT patients. Inogen estimates a full POC penetration rate to be 90% of the existing ambulatory patient population or ~70% of t
Slide 16: Design Expertise & Intellectual Property
Design Expertise & Intellectual Property 59 patents issued* System design and assembly Control systems for oxygen concentrators and ventilators Nasal interface designs Sieve bed designs and life prediction 29 pending patent applications* POC design improvements Ventilation interface design Design fe
Slide 17: Average Gross Non-delivery Ambulatory Monthly Rates
Average Gross non-delivery Ambulatory Monthly Rates We believe lower reimbursement rates will drive conversion to non-delivery solutions, although there are challenges to HME provider adoption POC reimbursement rates are an 18% premium compared to stationary + tanks in 36-mo rental period Oxygen was
Slide 18: COVID-19 Policy Changes
COVID-19 Policy Changes The CARES Act extended the 50/50 blended rate for HME providers in rural and non-contiguous, non-competitive bid areas & established a new 75/25 blended rate for all other non-competitive bid areas through duration of COVID-19 public health emergency Interim final rule publis
Slide 19: Strategic Value of New Aera Acquisition
Strategic Value of New Aera Acquisition Non-invasive ventilator (NIV) for select patients with chronic lung diseases (Rx required) Compatible with certain oxygen concentrators, oxygen cylinders, wall gas, and certain medical air sources Delivers higher flow and pressure versus traditional oxygen the
Slide 20: Benefits of TAV vs. Standard Oxygen
Benefits of TAV® vs. Standard Oxygen Randomized, open-label crossover study comparing TAV vs. standard oxygen for its impact on exercise endurance, oxygen saturation and Borg dyspnea 18 subjects included moderate to very severe COPD or interstitial lung disease patients studied at a pulmonary rehabi
Slide 21: A Proven Team Built for Success
A Proven Team Built for Success Ali Bauerlein CFO, EVP Finance, Corporate Secretary & Corporate Treasurer Scott Wilkinson* President, Chief Executive Officer, BOD Member Co-founder of Inogen with 19 years experience in treasury, finance, accounting, risk management as well as strategic and tactical